06.10.2020 • News

K+S in Americas Sale Talks with Stone Canyon

Responding to market rumors, German potash and salt company K+S has confirmed it is in “very advanced negotiations” with US-based global industrial holding company Stone Canyon Industries Holdings about a potential sale of its Americas operating unit.

The Kassel-headquartered group stated that it expects the price to be $3.2 billion but added that agreements have not been signed and there is no certainty that a deal can be reached.

Having decided on the divestment in a move to generate value and reduce debt, K+S mandated banks in March to sell the business, which includes salt operations in North and South America, as well as Morton Salt and K+S Chile. The company’s new 2 million t/y potash mine in Bethune, Saskatchewan, Canada, is not part of the sale.

Stone Canyon already operates a salt business. It created SCI Salt, following the $2 billion acquisition on Apr. 1 of Kissner, a US producer of bulk, specialty and evaporated salt. Kissner’s operations comprise two rock salt mines in Detroit, Michigan, and Lyons, Kansas; an evaporated salt business, including a refinery in Watkins Glen, New York; three salt production facilities co-located on potash mines in Western Canada; multiple packaging facilities and a network of distribution and storage facilities throughout the US.

 

Author: Elaine Burridge, Freelance Journalist

German potash company K+S has confirmed it is in “very advanced...
German potash company K+S has confirmed it is in “very advanced negotiations” with US-based global industrial holding company Stone Canyon Industries Holdings about a potential sale of its Americas operating unit. The price is expected to be $3.2 billion. (c) K+S Aktiengesellschaft

Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.